G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)

Type 2 Diabetes Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02726256
• Other study ID #: 3-2010-0195
• Status: Not yet recruiting
• Phase: N/A
• First received: March 27, 2016
• Last updated: April 15, 2016
• Start date: January 2007
• Est. completion date: February 2026

Study information

• Verified date: April 2016
• Source: Yonsei University
• Contact: Chul Woo Ahn, MD
• Phone: 82-02-2019-3339
• Email: acw[@]yuhs.ac
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications. Diabetes develops due to glucose intolerance. Early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications. This study was designed to make a cohort of korean patients with glucose intolerance to construct a long term database about clinical characteristics of these patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: February 2026
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Patients older than 20 years old who has visited Gangnam severance hospital since January 2007.

2. Patients with either diabetes or impaired glucose tolerance

3. Patients with at least 6 months of follow-up period

Exclusion Criteria:

1. Patients with gestational diabetes, any active stage of cancer and severe disability

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Glucose Intolerance
• Impaired Glucose Intolerance
• Type 2 Diabetes

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Yonsei University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Life style assessment - Past medical history - Smoking, alcohol history - Sleep, exercise, daily activity check - Diet - Reproductive status (Women only) - Socioeconomic status	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Past medical history	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Smoking, alcohol history	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Sleep, exercise, daily activity check	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Diet	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Reproductive status (Women only)	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Socioeconomic status	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Anthropometric measurements : Height, weight, waist circumference, pulse rate, blood pressure	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	SMA, TG, HDL, LDLM apoA, apoB	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	PC2hrs, HbA1C, Insulin, C-peptide (AC, PC2hr), hs-CRP	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Urine protein, albumin, creatinine	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	EKG, Neurometer, Chest PA, Abdominal sonography	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	Fundus photography, fat computed tomography	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No
Primary	HOMA-IR, HOMA-ß	Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications	an expected average of 12 weeks	No